Apitope News

Latest Press Releases

Apitope announces positive ATX-MS-1467 phase IIa data in relapsing Multiple Sclerosis

February 21, 2017

Hasselt, Belgium and Chepstow, UK: 21 February 2017 − Apitope, the drug discovery and development company focused on treating the underlying cause of autoimmune diseases, announces positive results from the Phase IIa clinical study of its lead product candidate, ATX-MS-1467, for the treatment of patients with multiple sclerosis. The Phase IIa, open-label, one arm study…

Details

Apitope Featured in the Report: 60 Years of Immunology

November 15, 2016

Hasselt, Belgium and Chepstow, UK: 15 November 2016 − Apitope, the clinical stage company focused on treating the underlying cause of autoimmune diseases, is pleased to announce that Apitope is featured in the 60 Years of Immunology report by the British Society for Immunology (BSI). In the report, Professor David Wraith, Founder & Chief Scientific…

Details

Apitope Announces Enrolment of First Patient in Phase I Trial of ATX-GD-59 for the Treatment of Graves’ Disease

October 26, 2016

Hasselt, Belgium and Chepstow, UK: 26th October 2016 − Apitope, the drug discovery and development company focused on treating the underlying cause of autoimmune diseases, today announces that the first patient has been enrolled in the Phase I clinical trial of its novel peptide therapy, ATX-GD-59, for the treatment of Graves’ disease. Apitope’s ATX-GD-59 has…

Details

Apitope regains global rights to its novel treatment for multiple sclerosis from Merck KGaA, Darmstadt, Germany.

October 17, 2016

Chepstow, UK and Hasselt, Belgium: October 17 2016 − Apitope is a drug discovery and development company focused on highly selective therapies that reinstate immune tolerance and thereby treat the underlying cause of autoimmune, as well as allergic diseases. Today Apitope announces it has regained global rights to its compound, ATX-MS-1467, a potentially disease-modifying therapy…

Details

Apitope awarded venture capital deal of the year at Wales dealmakers awards 2016

September 30, 2016

Cardiff, UK and Hasselt, Belgium: 27th September 2016 − Apitope, the drug discovery and development company focused on treating the underlying cause of autoimmune diseases, is pleased to announce it has won the “Venture Capital Deal of the Year” Award at the Wales Dealmakers Awards 2016 for its €12 million fundraising in September 2015. The…

Details

Apitope to Present at Bio€quity Europe in May 2016

May 9, 2016

Cardiff, UK and Hasselt, Belgium: 9 May 2016 − Apitope, the drug discovery and development company focused on treating the underlying cause of autoimmune diseases, today announces that Dr Keith Martin, CEO of Apitope, is scheduled to present at Bio€quity Europe on Tuesday, 10 May 2016 at 2.20 pm CET at the Scandic Hotel, Copenhagen,…

Details